Accès gratuit
Numéro
Med Sci (Paris)
Volume 30, Numéro 4, Avril 2014
Page(s) 452 - 461
Section Microenvironnements tumoraux : conflictuels et complémentaires
DOI https://doi.org/10.1051/medsci/20143004022
Publié en ligne 5 mai 2014
  1. Wong S, Witte ON. The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 2004 ; 22 : 247–306. [CrossRef] [PubMed]
  2. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 2013 ; 122 : 872–884. [CrossRef] [PubMed]
  3. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 2010 ; 11 : 1029–1035. [CrossRef] [PubMed]
  4. Chomel JC, Bonnet ML, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 2011 ; 118 : 3657–3660. [CrossRef] [PubMed]
  5. Li L, Bhatia R. Stem cell quiescence. Clin Cancer Res 2011 ; 17 : 4936–4941. [CrossRef] [PubMed]
  6. Faubert A, Chagraoui J, Mayotte N, et al. Complementary and independent function for Hoxb4 and Bmi1 in HSC activity. Cold Spring Harb Symp Quant Biol 2008 ; 73 : 555–564. [CrossRef] [PubMed]
  7. Schofield R. The relationship between the spleen colony-forming cell and the haemopoietic stem cell. Blood Cells 1978 ; 4 : 7–25. [PubMed]
  8. Lataillade JJ, Brunet de La Grange P, Uzan G, Le Bousse-Kerdiles MC. Les cellules souches ont-elles l’âge de leur niche ? À la recherche d’un sérum de jouvence. Med Sci (Paris) 2010 ; 26 : 582–585. [CrossRef] [EDP Sciences] [PubMed]
  9. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008 ; 8 : 290–301. [CrossRef] [PubMed]
  10. Frenette PS, Pinho S, Lucas D, Scheiermann C. Mesenchymal stem cell: keystone of the hematopoietic stem cell niche and a stepping-stone for regenerative medicine. Annu Rev Immunol 2013 ; 31 : 285–316. [CrossRef] [PubMed]
  11. Rizo A, Vellenga E, de Haan G, Schuringa JJ. Signaling pathways in self-renewing hematopoietic and leukemic stem cells: do all stem cells need a niche? Hum Mol Genet 2006 ; 15 (suppl 2) : R210–R219. [CrossRef] [PubMed]
  12. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006 ; 6 : 93–106. [CrossRef] [PubMed]
  13. Gordon MY, Dowding CR, Riley GP, et al. Altered adhesive interactions with marrow stroma of haematopoietic progenitor cells in chronic myeloid leukaemia. Nature 1987 ; 328 : 342–344. [CrossRef] [PubMed]
  14. Verfaillie CM, McCarthy JB, McGlave PB. Mechanisms underlying abnormal trafficking of malignant progenitors in chronic myelogenous leukemia. Decreased adhesion to stroma and fibronectin but increased adhesion to the basement membrane components laminin and collagen type IV. J Clin Invest 1992 ; 90 : 1232–1241. [CrossRef] [PubMed]
  15. Salgia R, Quackenbush E, Lin J, et al. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood 1999 ; 94 : 4233–4246. [PubMed]
  16. Geay JF, Buet D, Zhang Y, et al. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression. Cancer Res 2005 ; 65 : 2676–2683. [CrossRef] [PubMed]
  17. Krause DS, Lazarides K, von Andrian UH, Van Etten RA. Requirement for CD44 in homing and engraftment of BCR-ABL-expressing leukemic stem cells. Nat Med 2006 ; 12 : 1175–1180. [CrossRef] [PubMed]
  18. Flamant S, Kortulewski T, Dugray A, et al. Osteopontin is upregulated by BCR-ABL. Biochem Biophys Res Commun 2005 ; 333 : 1378–1384. [CrossRef] [PubMed]
  19. Bhatia R, McCarthy JB, Verfaillie CM. Interferon-alpha restores normal beta 1 integrin-mediated inhibition of hematopoietic progenitor proliferation by the marrow microenvironment in chronic myelogenous leukemia. Blood 1996 ; 87 : 3883–3891. [PubMed]
  20. Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia 1998 ; 12 : 1708–1717. [CrossRef] [PubMed]
  21. Jin L, Tabe Y, Konoplev S, et al. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells. Mol Cancer Ther 2008 ; 7 : 48–58. [CrossRef] [PubMed]
  22. Schepers K, Pietras EM, Reynaud D, et al. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche. Cell Stem Cell 2013 ; 13 : 285–299. [CrossRef] [PubMed]
  23. Schmidt T, Kharabi Masouleh B, Loges S, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011 ; 19 : 740–753. [CrossRef] [PubMed]
  24. Yamamoto-Sugitani M, Kuroda J, Ashihara E, et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci USA 2011 ; 108 : 17468–17473. [CrossRef]
  25. Laperrousaz B, Jeanpierre S, Sagorny K, et al. Primitive CML cell expansion relies on abnormal levels of BMPs provided by the niche and on BMPRIb overexpression. Blood 2013 ; 122 : 3767–3777. [CrossRef] [PubMed]
  26. Nair RR, Tolentino J, Hazlehurst LA. The bone marrow microenvironment as a sanctuary for minimal residual disease in CML. Biochem Pharmacol 2010 ; 80 : 602–612. [CrossRef] [PubMed]
  27. Nwajei F, Konopleva M., The bone marrow microenvironment as niche retreats for hematopoietic and leukemic stem cells. Adv Hematol 2013 ; 2013 : 953982. [CrossRef] [PubMed]
  28. Krause DS, Scadden DT, Preffer FI. The hematopoietic stem cell niche: home for friend and foe? Cytometry B Clin Cytom 2013 ; 84 : 7–20. [CrossRef] [PubMed]
  29. Forkner CE, Scott TF. Arsenic as a therapeutic agent in chronic myelogenous leukemia. JAMA 1931 ; 97 : 3–5. [CrossRef]
  30. Guo-Bao W, Xiao-Qin C, Qi-Rong G, et al. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta1-integrin in K562 chronic myelogenous leukemia cell line. Leuk Lymphoma 2010 ; 51 : 1090–1097. [CrossRef] [PubMed]
  31. Agarwal A, Fleischman AG, Petersen CL, et al. Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML. Blood 2012 ; 120 : 2658–2668. [CrossRef] [PubMed]
  32. Weisberg E, Azab AK, Manley PW, et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012 ; 26 : 985–990. [CrossRef] [PubMed]
  33. Galaup A, Germain S. Les anticorps anti-PlGF. Un nouvel outil thérapeutique anti-angiogénique ? Med Sci (Paris) 2008 ; 24 : 459–462. [CrossRef] [EDP Sciences] [PubMed]
  34. Boyerinas B, Zafrir M, Yesilkanal AE, et al. Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy. Blood 2013 ; 121 : 4821–4831. [CrossRef] [PubMed]
  35. Nilsson SK, Haylock DN, Johnston HM, et al. Hyaluronan is synthesized by primitive hemopoietic cells, participates in their lodgment at the endosteum following transplantation, and is involved in the regulation of their proliferation and differentiation in vitro. Blood 2003 ; 101 : 856–862. [CrossRef] [PubMed]
  36. Arai F, Hirao A, Ohmura M, et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004 ; 118 : 149–161. [CrossRef] [PubMed]
  37. Zhang J, Niu C, Ye L, et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003 ; 425 : 836–841. [CrossRef] [PubMed]
  38. Bhatia M, Bonnet D, Wu D, et al. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells. J Exp Med 1999 ; 189 : 1139–1148. [CrossRef] [PubMed]
  39. Adams GB, Chabner KT, Alley IR, et al. Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor. Nature 2006 ; 439 : 599–603. [CrossRef] [PubMed]
  40. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006 ; 25 : 977–988. [CrossRef] [PubMed]
  41. Itkin T, Kaufmann KB, Gur-Cohen S, et al. Fibroblast growth factor signaling promotes physiological bone remodeling and stem cell self-renewal. Curr Opin Hematol 2013 ; 20 : 237–244. [PubMed]
  42. Teixido J, Hemler ME, Greenberger JS, Anklesaria P. Role of beta 1 and beta 2 integrins in the adhesion of human CD34hi stem cells to bone marrow stroma. J Clin Invest 1992 ; 90 : 358–367. [CrossRef] [PubMed]
  43. Pruijt JF, van Kooyk Y, Figdor CG, et al. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood 1998 ; 91 : 4099–4105. [PubMed]
  44. Mancini SJ, Mantei N, Dumortier A, et al. Jagged1-dependent Notch signaling is dispensable for hematopoietic stem cell self-renewal and differentiation. Blood 2005 ; 105 : 2340–2342. [CrossRef] [PubMed]
  45. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol 2008 ; 180 : 7358–7367. [CrossRef] [PubMed]
  46. Arai F, Hosokawa K, Toyama H, et al. Role of N-cadherin in the regulation of hematopoietic stem cells in the bone marrow niche. Ann NY Acad Sci 2012 ; 1266 : 72–77. [CrossRef]
  47. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005 ; 106 : 1232–1239. [CrossRef] [PubMed]
  48. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003 ; 425 : 841–846. [CrossRef] [PubMed]
  49. Kovach NL, Lin N, Yednock T, et al. Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines. Blood 1995 ; 85 : 159–167. [PubMed]
  50. Driessen RL, Johnston HM, Nilsson SK. Membrane-bound stem cell factor is a key regulator in the initial lodgment of stem cells within the endosteal marrow region. Exp Hematol 2003 ; 31 : 1284–1291. [CrossRef] [PubMed]
  51. Bhardwaj G, Murdoch B, Wu D, et al. Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat Immunol 2001 ; 2 : 172–180. [CrossRef] [PubMed]
  52. Dimitroff CJ, Lee JY, Rafii S, et al. CD44 is a major E-selectin ligand on human hematopoietic progenitor cells. J Cell Biol 2001 ; 153 : 1277–1286. [CrossRef] [PubMed]
  53. Yamazaki S, Ema H, Karlsson G, et al. Nonmyelinating Schwann cells maintain hematopoietic stem cell hibernation in the bone marrow niche. Cell 2011 ; 147 : 1146–1158. [CrossRef] [PubMed]
  54. Yoshihara H, Arai F, Hosokawa K, et al. Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell 2007 ; 1 : 685–697. [CrossRef] [PubMed]
  55. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003 ; 423 : 409–414. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.